- The acquisition of the Orth pharmaceutical and biotech site represents a significant milestone in Infrareal Group’s expansion strategy.
- PharmaparkOrth Management GmbH will become the owner and operator of the pharmaceutical and biotech site in Austria as a subsidiary of Infrareal Holding GmbH & Co. KG.
- As of 31 May 2025, Infrareal will take over more than 30 employees at the site, whose expertise will ensure the reliable continuation of operations and drive further development and expansion.
The acquisition represents a significant advancement in Infrareal Group’s strategy to establish itself as one of Europe’s leading operators of pharmaceutical and life science parks. “I am very grateful and proud of my colleagues, who have put in many months of hard work together with the Takeda team. The successful conclusion of this transaction marks a milestone in our company’s history”, says Dr Martin Egger, CEO and spokesman of the Infrareal Management Board.
At the Pharma Park in Orth, the existing buildings and facilities will be supplemented by the development and marketing of open areas to enable further growth. Conversations with several companies interested from the biotechnology sector are in progress already. Through synergies and innovative infrastructure solutions, Infrareal creates opportunities for optimisation and growth at all its sites. This enables long-term prospects for companies in the pharmaceutical, biotech, and life science sectors.
“We look forward to working with the Infrareal Group. As owner and operator, they have a clear goal of further developing the Orth site, creating synergies and continuing to promote sustainable processes and decarbonisation”, says Christian Froeschl-Drahos, Site Quality Lead at Takeda in Orth.
Orth is an attractive location for international biopharmaceutical companies thanks to its facilities and infrastructure, highly qualified workforce and proximity to Vienna International Airport and the Austrian capital.
Alongside Takeda, another major international pharmaceutical company, Pfizer Manufacturing GmbH, is located at the site. “We are pleased with the Infrareal Group’s decision to invest at this site. It shows that they are as well convinced of the great potential of the Orth pharmaceutical and biotech site, which will further strengthen our region”, says Elisabeth Wagnes, Mayor of Orth, who was unable to welcome the new owners in person. Josef Drabits, Deputy Mayor of Orth, represented her and took the opportunity to get to know the site and its employees.
Contact for enquiries
Infrareal Holding GmbH & Co.KGKerstin von Heemskerck
Director Corporate Communications & Marketing
Email: http://mailto:kerstin.vonheemskerck@infrareal.de
